Choosing between Wegovy and the Wegovy FlexTouch Pen is often a matter of terminology rather than treatment. Wegovy is the weight management medicine containing semaglutide, while the Wegovy FlexTouch Pen is the injection device used to administer it. In practice, people searching for "Wegovy vs Wegovy FlexTouch" are often trying to understand the difference between the Wegovy pen and other treatment options, such as Mounjaro. While both Wegovy and Mounjaro are once-weekly prescription injections used to support long-term weight management, they differ in their active ingredients, how they work, dose escalation schedules, storage requirements, travel guidance, clinical evidence, pricing, and overall treatment approach.
At EverydayMeds, we provide access to Wegovy and Mounjaro through our secure UK online prescribing service for adults seeking medically supervised weight management treatment. Our clinical team assesses whether a treatment may be suitable based on your medical history, BMI, lifestyle, weight management goals, and, where appropriate, local availability and prescribing considerations that may influence which treatment or device is prescribed. Whether you are starting treatment for the first time or considering switching, understanding these differences can help you make a more informed decision. The medicine, dosing schedule, injection device, and day-to-day practicalities may all influence which treatment is more suitable for your needs.
Unlike many pharmacies that stock only selected strengths, EverydayMeds aims to maintain availability across the full range of Wegovy and Mounjaro dose strengths, subject to stock availability. This may help reduce the likelihood of treatment interruptions where stock is available and support a smoother progression through your prescribed dose escalation plan.
Wegovy vs Mounjaro Weight-Management Medicine at a Glance
| Feature | Wegovy FlexTouch Pen | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Medicine type | GLP-1 receptor agonist | Dual GIP & GLP-1 receptor agonist |
| Weekly injections | Yes | Yes |
| Starting dose | 0.25mg | 2.5mg |
| Maximum dose | 2.4mg | 15mg |
| Dose strengths | 5 | 6 |
| Room temperature storage | Up to 6 weeks | Up to 21 days |
| Prescription required | Yes | Yes |
| UK licensed | Yes | Yes |
This comparison provides a quick overview, but the best option depends on your individual health profile, treatment goals, and response to medication.
What Is the Wegovy FlexTouch Pen?
The Wegovy FlexTouch Pen is a pre-filled, dial-a-dose pen for subcutaneous injection that contains semaglutide, a GLP-1 receptor agonist. It is prescribed as part of a medically supervised weight management programme alongside a reduced-calorie diet and increased physical activity.
Treatment follows a gradual dose escalation schedule, starting at 0.25mg once weekly for 4 weeks and increasing to 2.4mg once weekly after 17 weeks. Each Wegovy FlexTouch Pen is a multi-dose, pre-filled pen that contains four doses. It is designed for self-administration at home and is used with replaceable needles until all four doses have been used. The dose selector allows users to dial their prescribed dose before each injection.
Many patients consider the Wegovy FlexTouch Pen a practical option because of its easy-to-use design, dose selector, and room-temperature storage within the manufacturer's guidance. These features may make it a convenient choice for people with busy lifestyles or those who travel frequently.
What Is Mounjaro?
Mounjaro contains tirzepatide, a medicine that activates both GIP and GLP-1 receptors. It is prescribed as an option for eligible adults as part of a medically supervised weight management programme.
Like Wegovy, Mounjaro is administered once a week using a pre-filled injection pen. Treatment starts with a lower dose and gradually increases over time. This dose escalation schedule allows the body to adjust and may help reduce the likelihood of common gastrointestinal side effects.
Mounjaro is available in six dose strengths. Depending on your response to treatment and your prescriber's recommendations, you may remain on a particular dose for longer before moving to the next strength.
Key Differences Between Wegovy and Mounjaro
Although both medicines are designed to support weight management, they work in different ways and have distinct treatment pathways.
Active Ingredient
Wegovy contains semaglutide, while Mounjaro contains tirzepatide. These medicines belong to the same general family of injectable weight management treatments but act on different receptors. Wegovy and Ozempic have the same active ingredient, but Ozempic is not approved for weight loss in the UK.
Mechanism of Action and Injection Site
Wegovy works by activating GLP-1 receptors. It is designed to help regulate appetite and increase feelings of fullness as part of a medically supervised weight management programme. It also slows gastric emptying, which may help reduce food intake.
Mounjaro activates both GLP-1 and GIP receptors, giving it a dual mechanism of action. This may affect appetite and metabolic processes differently from Wegovy. Both medicines are licensed to support weight management alongside a reduced-calorie diet and increased physical activity, although they work through different receptor pathways.
Dose Escalation
Wegovy follows a five-stage escalation:
- 0.25mg
- 0.5mg
- 1mg
- 1.7mg
- 2.4mg
Mounjaro follows six stages, with a maximum dosage of 15mg weekly:
- 2.5mg
- 5mg
- 7.5mg
- 10mg
- 12.5mg
- 15mg
Both treatment plans are designed to improve tolerability through gradual dose increases. Each dose increase may make side effects more noticeable for some patients, which is why prescribers may slow a step up if needed.
Similarities Between Wegovy and Mounjaro
Despite their differences, both medicines share several important characteristics:
- Once-weekly injections
- Prescription-only medicines
- Used alongside a reduced-calorie diet and increased physical activity
- Online clinical assessment required before prescribing
- Gradual dose escalation
- Prescription weight management injections
- Suitable for self-injection at home following appropriate guidance
- Temperature-controlled delivery
- Used as part of a long-term weight management programme when prescribed appropriately
- Available through EverydayMeds
Both are prescription-only weight management medicines that should only be used under the guidance of a qualified healthcare professional.
How Wegovy and Mounjaro Work
Although Wegovy and Mounjaro are both once-weekly injectable medicines for weight management, they contain different active ingredients and work in different ways within the body.
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the naturally occurring GLP-1 hormone released after eating. This hormone plays a role in appetite regulation by signalling to the brain that you feel full and slowing stomach emptying. Some people may notice changes in their appetite while following their prescribed treatment plan alongside a reduced-calorie diet.
Mounjaro contains tirzepatide, which activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism of action affects different receptor pathways from Wegovy. Both medicines are prescribed as part of a weight management programme alongside a reduced-calorie diet and increased physical activity rather than as standalone treatments.
Both medicines are administered once a week using pre-filled injection pens and should only be used under the supervision of a qualified healthcare professional.
Wegovy vs Mounjaro Dose Escalation
One of the biggest differences between the two medications is their dose escalation schedule.
Healthcare professionals gradually increase the dose over several weeks to help the body adjust and reduce the likelihood of gastrointestinal side effects such as nausea or vomiting.
| Treatment Stage | Wegovy | Mounjaro |
|---|---|---|
| Starting Dose | 0.25mg | 2.5mg |
| Second Stage | 0.5mg | 5mg |
| Third Stage | 1mg | 7.5mg |
| Fourth Stage | 1.7mg | 10mg |
| Fifth Stage | 2.4mg | 12.5mg |
| Sixth Stage | — | 15mg |
Your prescriber may recommend remaining on a particular dose for longer if you require additional time to adjust before progressing.
Never increase your dose without medical advice.
Clinical Evidence Supporting Wegovy and Mounjaro
Both Wegovy and Mounjaro have been evaluated in large clinical trials for weight management when used alongside a reduced-calorie diet and increased physical activity. Results have varied between studies, treatment duration, and the groups of people included.
Clinical studies have reported that some participants achieved around 5% weight loss during the early stages of treatment. In some trials, 91% of participants lost at least 5% of their body weight. Longer-term studies have also reported average weight reductions of around 21% in selected study populations over approximately 72 weeks, while other studies have reported average weight reductions of 20.7% over 18 months.
In a cardiovascular outcomes trial involving adults with overweight or obesity and established cardiovascular disease, Wegovy was associated with a 20% reduction in the risk of major adverse cardiovascular events. Improvements in cardiovascular risk factors, including blood pressure, have also been investigated in clinical studies.
Wegovy Clinical Studies
The STEP clinical trial programme evaluated semaglutide in adults living with obesity or overweight.
Results from the landmark STEP 1 trial showed that participants receiving semaglutide alongside lifestyle interventions achieved significantly greater average weight loss over 68 weeks compared with those receiving placebo. Some participants achieved approximately 5% weight loss during the first three months of treatment in clinical studies. Longer-term STEP findings also showed that some longer-term clinical studies reported average weight reductions of around 21% in selected study populations over approximately 72 weeks, with weight loss reaching 20.7% over 18 months. In clinical trials, 91% of Wegovy users lost at least 5% of weight, and in a cardiovascular outcomes trial involving adults with overweight or obesity and established cardiovascular disease, Wegovy reduced the risk of major adverse cardiovascular events by 20%.
Additional STEP studies also examined long-term treatment, patients with type 2 diabetes, and cardiovascular outcomes, supporting Wegovy's role as an evidence-based weight management treatment.
Mounjaro Clinical Studies
Mounjaro has been investigated in clinical trials that assessed tirzepatide for chronic weight management.
Clinical studies demonstrated substantial reductions in body weight among eligible participants when tirzepatide was combined with dietary changes and regular physical activity. Some comparisons also suggest tirzepatide may help certain patients lose more weight than semaglutide-based treatment, though individual response still varies.
Although both treatment programmes produced positive outcomes, direct comparisons between individual patients should always be made by a qualified healthcare professional rather than relying solely on published averages.
Pricing Comparison
The overall cost of treatment depends on your prescribed dose, the length of treatment, and whether you purchase individual pens or treatment bundles. For comparison, Mounjaro treatment currently starts from £88.97 for a four-week supply.
Wegovy Pricing
| Dose | Price |
|---|---|
| 0.25mg | £79* |
| 0.5mg | £94.99 |
| 1mg | £99.99 |
| 1.7mg | £139.99 |
| 2.4mg | £199 per month |
*Initial 0.25mg pricing is £79. Subsequent 0.25mg orders increased to £119. Each Wegovy pen price reflects the strength supplied for that stage of treatment and the monthly supply.
New customers can apply the FIRST40 discount code at checkout.
Returning patients can continue saving with the DOSE25 discount code on eligible orders.
Bundle Options
EverydayMeds also offers treatment bundles designed to simplify dose progression, helping patients plan future treatment and potentially reduce the likelihood of interruptions while planning their long-term treatment journey.
Storage Comparison
Correct storage is essential to maintain product quality when injectable medications are stored according to the manufacturer's instructions.
| Storage Feature | Wegovy | Mounjaro |
|---|---|---|
| Refrigerated before use | ✔ | ✔ |
| Store at 2°C–8°C | ✔ | ✔ |
| Room temperature after removal | Up to 6 weeks | Up to 21 days |
| Freeze | ✘ | ✘ |
| Protect from direct sunlight | ✔ | ✔ |
Once delivered, store Wegovy in a refrigerator at 2°C–8°C, or at room temperature for up to 6 weeks after removal, while keeping it away from direct sunlight.
For patients who travel frequently or spend time away from home, Wegovy's longer room-temperature storage period may offer additional convenience.
Travelling with Wegovy or Mounjaro
If you travel regularly for work or leisure, storage flexibility may influence your choice of medication.
Wegovy can generally remain below 30°C for up to six weeks after being removed from refrigeration, making it particularly suitable for extended holidays or business trips. When appropriate, let the pen reach room temperature before use, following the storage guidance provided with your treatment.
Mounjaro has a shorter room-temperature storage window, so additional planning may be required when travelling for longer periods.
Regardless of which medication you use, always transport your injection pen according to the manufacturer's storage recommendations and avoid exposing it to excessive heat or freezing temperatures.
Which Medication May Be Right for You?
There is no single treatment that is suitable for everyone. The right choice depends on your medical history, weight management goals, current health conditions, previous treatments, and how well you tolerate dose escalation.
Wegovy may be suitable if you:
- Prefer a well-established GLP-1 receptor agonist.
- Want a structured five-stage dose escalation plan.
- Travel frequently and benefit from longer room-temperature storage.
- Are looking for a simple once-weekly treatment supported by extensive clinical research.
Mounjaro may be suitable if you:
- Are clinically appropriate for tirzepatide treatment.
- Prefer a medication that acts on both GIP and GLP-1 receptors.
- Have discussed this treatment option with your prescriber.
- Are comfortable following a six-stage dose escalation schedule.
Your online clinical assessment helps our qualified prescribers determine which medication is the most appropriate option based on your individual circumstances.
Why Choose EverydayMeds?
Selecting the right online pharmacy is just as important as selecting the right medication.
At EverydayMeds, patient safety, clinical oversight, and treatment continuity are at the heart of everything we do. Our aim is to provide a reliable, convenient, and medically supervised service that supports your prescribed weight-management treatment from your first consultation through to long-term maintenance, including for eligible adults with obesity-related conditions as part of a supported weight loss journey. Suitability is assessed using the clinical information you provide, including factors such as body mass index.
Complete Dose Availability
We aim to maintain stock of the full range of Wegovy and Mounjaro strengths, subject to availability, helping patients move through their prescribed treatment plans without unnecessary interruptions.
Qualified UK Prescribers
Every online assessment is reviewed by a qualified prescriber who evaluates your medical history, current medications, BMI, and treatment goals before issuing a prescription.
GPhC-Registered Pharmacy
All medicines are supplied through our GPhC-registered pharmacy (#9012878) and dispensed in accordance with UK pharmacy standards.
Fast Online Assessment
Our secure online questionnaire typically takes around three minutes to complete, allowing you to begin your assessment from the comfort of your home.
Temperature-Controlled Delivery
Approved prescriptions are dispatched using specialist cold-chain packaging with temperature monitoring to help maintain the required storage conditions during transport.
Ongoing Clinical Support
Support continues after delivery for patients receiving ongoing treatment, including guidance on dose progression, ordering and general treatment queries. As a medically supervised weight loss service, EverydayMeds gives patients ongoing guidance throughout their treatment journey, including help with your next dose and general treatment questions.
How to Order Wegovy or Mounjaro Online
Ordering prescription weight-management treatment through EverydayMeds is straightforward.
Step 1 – Complete the Online Assessment
Fill in our secure medical questionnaire with details about your weight, BMI, medical history, current medications, and treatment goals, so our clinical team helps the prescriber assess whether treatment is clinically appropriate.
Step 2 – Clinical Review
One of our qualified prescribers carefully reviews your assessment to determine whether Wegovy or Mounjaro is clinically appropriate.
Step 3 – Prescription Approval
If approved, your prescription is issued and prepared for dispensing by our pharmacy team. Before starting treatment, read the patient information leaflet for full guidance on dosage, administration, and safety.
Step 4 – Cold-Chain Delivery
Your medication is packaged in temperature-controlled packaging and dispatched using next-day delivery, helping ensure it arrives in the correct condition.
